Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 9, 2011, Pages 1301-1308

  Keam, Bhumsuk ^a   Im, Seock Ah ^a   Park, Sohee ^b   Nam, Byung Ho ^b   Han, Sae Won ^a   Oh, Do Youn ^a   Kim, Jee Hyun ^a,c   Lee, Se Hoon ^a   Han, Wonshik ^a   Kim, Dong Wan ^a   Kim, Tae You ^a   Park, In Ae ^a   Noh, Dong Young ^a   Heo, Dae Seog ^a   Bang, Yung Jue ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Nomogram; Prediction

Indexed keywords

DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NOMOGRAM; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NOMOGRAMS; PROGNOSIS; TAXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054772543     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-0991-3     Document Type: Article

References (33)

1. Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S (2005) An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Br Cancer Res Treat 91:113-119 (Pubitemid 40684923)
2. Colleoni M, Bagnardi V, Rotmensz N, Dellapasqua S, Viale G, Pruneri G, Veronesi P, Torrisi R, Luini A, Intra M, Galimberti V, Montagna E, Goldhirsch A (2009) A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol 20:1178-1184
3. Estevez LG, Gradishar WJ (2004) Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10:3249-3261 (Pubitemid 38685428)
4. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic Index in primary breast cancer. Br Cancer Res Treat 22:207-219
5. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26:814-819 (Pubitemid 351265335)
6. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M (2002) AJCC cancer staging manual, 6th edn. Springer, New York
7. Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36 (Pubitemid 12142173)
8. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387 (Pubitemid 26072233)
9. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56:337-344 (Pubitemid 30422619)
10. Hosmer DW, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York
11. Iasonos A, Schrag D, Raj GV, Panageas KS (2008) How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 26:1364-1370
12. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK (2008a) Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 26:246-252
13. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK (2008b) Staging of breast cancer in the neoadjuvant setting. Cancer Res 68:6477-6481
14. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Br Cancer Res Treat 116:53-68
15. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M (2010) Relationship between oestrogen receptor status and proliferation in predicting response and longterm outcome to neoadjuvant chemotherapy for breast cancer. Br Cancer Res Treat 119:315-323
16. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ (2007) Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7:203
17. Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ (2009) Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Br Cancer Res Treat 116:153-160
18. Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH, Lee SH, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Bang YJ (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Br Cancer Res 13:R22
19. Kohrt HE, Olshen RA, Bermas HR, Goodson WH, Wood DJ, Henry S, Rouse RV, Bailey L, Philben VJ, Dirbas FM, Dunn JJ, Johnson DL, Wapnir IL, Carlson RW, Stockdale FE, Hansen NM, Jeffrey SS (2008) New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 8:66
20. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ (2007) Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 7:63
21. Lemeshow S, Hosmer DW Jr (1982) A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 115:92-106 (Pubitemid 12205725)
22. Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Pusztai L (2007) Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25:2650-2655 (Pubitemid 47123169)
23. Nam BH (2000) Discrimination and calibration in survival analysis, Doctoral dissertation. Boston University, Boston, MA
24. Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109-2123 (Pubitemid 38968032)
25. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991 (Pubitemid 32176272)
26. Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN (2005) Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-8339
27. Rouzier R, Pusztai L, Garbay JR, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM (2006) Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 107:1459-1466 (Pubitemid 44546904)
28. Shimizu C, Ando M, Kouno T, Katsumata N, Fujiwara Y (2007) Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol 37:1-8 (Pubitemid 47090717)
29. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422 (Pubitemid 350013847)
30. Unal B, Gur AS, Ahrendt G, Johnson R, Bonaventura M, Soran A (2009) Can nomograms predict non-sentinel lymph node metastasis after neoadjuvant chemotherapy in sentinel lymph nodepositive breast cancer patients? Clin Br Cancer 9:92-95
31. Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS III, Kattan MW (2003) A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10:1140-1151 (Pubitemid 40486808)
32. Yip CH (2009) Breast cancer in Asia. Methods Mol Biol 471:51-64
33. Yoo KY, Kang D, Park SK, Kim SU, Shin A, Yoon H, Ahn SH, Noh DY, Choe KJ (2002) Epidemiology of breast cancer in Korea: occurrence, high-risk groups, and prevention. J Korean Med Sci 17:1-6